SOLICITATION NOTICE
65 -- iPLEX Gold Reagent and SpectroCHIP
- Notice Date
- 4/20/2015
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2015-111-DLM
- Archive Date
- 5/12/2015
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Agena Bioscience, 3565 General Atomics Court, San Diego, California 92121 to procure the following: Procurement: 1. iPLEX® Gold Reagent and SpectroCHIP® Set 10x384, Product Code: 10134-2, Quantity: Two (2) Each; and 2. SpectroCHIP® Resin Kit 10x384, Product Code: 10117-2, Quantity: Two (2) Each. BACKGROUND: The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency seeking fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI), mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. A critical part of the NHGRI mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research. NHGRI is engaged in a large collaborative study in which more than 1380 subjects with neural tube defects, including approximately 950 parent and child trios are being studied. The research uses genome-wide genetic linkage and association to identify disease associated variants. The clinical researchers have developed and applied new high throughput genotyping approaches in the laboratory using the Sequenom platform, which have allowed the collection of a massive amount of data from these individuals with neural tube defects and their families. Following the genome wide association study (GWAS) approach, single nucleotide polymorphisms have been selected and genotyped using the Sequenom platform at NHGRI. Contributed to the identification and/or evaluation is no less than 82 loci for neural tube defects. The need to continue this approach is anticipated to continue this approach in identifying additional loci important in the development of neural tube defects. Agena Bioscience genotyping capabilities have been upgraded to increase throughput and versatility as well as lower the cost of high throughput SNP analysis. NHGRI clinical researchers continue to use iPlex Gold/SpectroCHIP II reagents in order to test as many as 36 SNPs in each multiplex reaction. These reagents are customized for the use with the Sequenom MassArray system and are not available from any other source. This system has been optimized in NHGRI laboratory for the "The Contribution of Folate and Vitamin B12 Genes to Disease study", clinical Protocol Number: Z1A-HG000167. PERIOD OF PERFORMANCE: Delivery Upon Award JUSTIFICATION: Agena Bioscience iPlex Gold/ SpectroCHIP II for Sequenom platform reagent system is important to the high throughput analysis of neural tube defect associated SNPs. Additionally, continue to assist NHGRI with their clinical high throughput analysis of neural tube defect associated SNPs and provide: • Use of an ultra-low amplification reaction volume of 5ul with potential to reduce to sub-microliter levels with advances in liquid handling technologies. • Ability to genotype samples with only 2.5 ng of genomic DNA in a 5-microliter reaction. • Use of standardized assay conditions requiring virtually no assay optimization permitting rapid establishment of new assays without significant development time. • Ability to detect small insertions and deletions in addition to SNPs with the standardized assay. • Ability to detect third alleles (tri-allelic SNPs) even if unexpected. Regulatory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source. ADDITIONAL INFORMATION: Industry Classification (NAICS) Code is541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology) and small business size standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-81 (April 10, 2015). This requirement is under the SAT of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received no later than 7:30 a.m. Eastern Standard Time (EST), April 27, 2015; and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2015-111-DLM, may be submitted to the National, Heart, Lung and Blood Institute, COAC Services Branch, Office of Acquisitions, Office of Management, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2015-111-DLM/listing.html)
- Place of Performance
- Address: NIH, 10 Center Drive, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03704639-W 20150422/150420235229-d9627d73d52506bde495fb83cdb8b81b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |